Alnylam earns development milestone payment from GSK
04:11 EDT 31 Jul 2012 | Pharmaceutical Business Review
Alnylam Pharmaceuticals, a RNAi therapeutics company, has earned a development milestone payment, totaling $3.2m from GlaxoSmithKline (GSK) in VaxiRNA collaboration on flu vaccine production.
Original Article: Alnylam earns development milestone payment from GSK
More From BioPortfolio on "Alnylam earns development milestone payment from GSK"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
